Lilly signs another AI deal, this one for obesity

In its latest push into artificial intelligence, Lilly has signed a deal with a California-based biotech to discover new obesity targets in humans. Fauna Bio says it will give Lilly access to its AI platform to support preclinical drug discovery efforts.... Read More

Lilly bracing for demand crush for newly approved obesity drug

The Indianapolis-based company said Wednesday that its newest product, a drug for obesity called Zepbound, will be on pharmacy shelves shortly after Thanksgiving. The company is ramping up manufacturing capacity to avoid possible shortages and to meet potentially huge demand in a nation where more than 40% of adults are classified as obese.... Read More